CPHI Online is the largest global marketplace in the pharma ingredients industry
Pipeline - Clindamycin Product Profile
Clindamycin 150mg/ml Solution for Injection (2ml & 4ml Amp) Dalacin® / Pfizer
Antibacterial. Serious infections caused by susceptible Gram-positive organisms,
staphylococci (both penicillinase- and non-penicillinase-producing),
streptococci (except Streptococcus faecalis) and pneumococci.
It is also indicated in serious infections caused by susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionibacterium spp, Peptostreptococcus spp. and microaerophilic streptococci.
Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities.
Dossier Status: On-going / EU CTD Available: 2022
Stability Studies: Zone II / Zone IVb
Shelf life (Originator): Two (2) years
Batch Sizes: To be defined
Pack Sizes: To be defined
Originator pack: Box x 1, 5 & 10 Ampoules.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance